Serge Muyldermans

33.6k total citations · 9 hit papers
291 papers, 25.6k citations indexed

About

Serge Muyldermans is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Immunology. According to data from OpenAlex, Serge Muyldermans has authored 291 papers receiving a total of 25.6k indexed citations (citations by other indexed papers that have themselves been cited), including 208 papers in Radiology, Nuclear Medicine and Imaging, 204 papers in Molecular Biology and 82 papers in Immunology. Recurrent topics in Serge Muyldermans's work include Monoclonal and Polyclonal Antibodies Research (205 papers), Glycosylation and Glycoproteins Research (106 papers) and Protein purification and stability (27 papers). Serge Muyldermans is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (205 papers), Glycosylation and Glycoproteins Research (106 papers) and Protein purification and stability (27 papers). Serge Muyldermans collaborates with scholars based in Belgium, China and United Kingdom. Serge Muyldermans's co-authors include Lode Wyns, Katja Conrath, Dirk Saerens, Nick Devoogdt, R. Hamers, Cécile Vincke, T. Atarhouch, Aline Desmyter, C. Hamers‐Casterman and Emmanuel Bajyana Songa and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Serge Muyldermans

286 papers receiving 25.1k citations

Hit Papers

Naturally occurring antib... 1993 2026 2004 2015 1993 2013 1997 2014 2007 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Naturally occurring antibodies devoid of light chains
    1993 2.4k citations C. Hamers‐Casterman, T. Atarhouch et al. Nature profile →
  2. Nanobodies: Natural Single-Domain Antibodies
    2013 1.6k citations Serge Muyldermans profile →
  3. Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies
    1997 622 citations Aline Desmyter, Serge Muyldermans et al. profile →
  4. A general protocol for the generation of Nanobodies for structural biology
    2014 554 citations Els Pardon, Toon Laeremans et al. Nature Protocols profile →
  5. A Versatile Nanotrap for Biochemical and Functional Studies with Fluorescent Fusion Proteins
    2007 547 citations Serge Muyldermans et al. profile →
  6. Targeting and tracing antigens in live cells with fluorescent nanobodies
    2006 544 citations Serge Muyldermans et al. profile →
  7. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies
    2006 514 citations Klaas Decanniere, Serge Muyldermans et al. profile →
  8. The Therapeutic Potential of Nanobodies
    2019 506 citations Ivana Jovčevska, Serge Muyldermans profile →
  9. Nanobody-based products as research and diagnostic tools
    2014 364 citations Serge Muyldermans et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Serge Muyldermans Belgium 80 16.6k 16.3k 5.8k 2.9k 2.2k 291 25.6k
Andreas Plückthun Switzerland 101 25.4k 1.5× 16.0k 1.0× 4.1k 0.7× 3.6k 1.2× 1.8k 0.8× 481 32.3k
Greg Winter United Kingdom 82 20.0k 1.2× 18.0k 1.1× 6.3k 1.1× 2.7k 0.9× 733 0.3× 179 27.8k
Pauline M. Rudd United Kingdom 90 21.1k 1.3× 7.8k 0.5× 8.4k 1.4× 1.7k 0.6× 939 0.4× 353 28.9k
K. Dane Wittrup United States 69 10.4k 0.6× 8.2k 0.5× 4.4k 0.8× 4.0k 1.4× 2.1k 0.9× 235 16.8k
Renata Pasqualini United States 69 12.0k 0.7× 4.4k 0.3× 2.1k 0.4× 4.4k 1.5× 2.4k 1.1× 243 20.5k
Georges Köhler Germany 44 11.1k 0.7× 11.0k 0.7× 10.1k 1.7× 3.1k 1.1× 617 0.3× 97 25.2k
César Milstein United Kingdom 77 18.4k 1.1× 17.7k 1.1× 13.9k 2.4× 3.4k 1.2× 776 0.3× 202 36.0k
Manfred Wuhrer Netherlands 80 15.1k 0.9× 6.7k 0.4× 6.2k 1.1× 833 0.3× 940 0.4× 443 20.8k
Richard D. Cummings United States 96 22.1k 1.3× 3.8k 0.2× 12.4k 2.1× 2.4k 0.8× 579 0.3× 513 33.1k
Dimiter S. Dimitrov United States 74 7.1k 0.4× 3.8k 0.2× 6.4k 1.1× 3.2k 1.1× 1.7k 0.7× 364 20.7k

Countries citing papers authored by Serge Muyldermans

Since Specialization
Citations

This map shows the geographic impact of Serge Muyldermans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Serge Muyldermans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Serge Muyldermans more than expected).

Fields of papers citing papers by Serge Muyldermans

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Serge Muyldermans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Serge Muyldermans. The network helps show where Serge Muyldermans may publish in the future.

Co-authorship network of co-authors of Serge Muyldermans

This figure shows the co-authorship network connecting the top 25 collaborators of Serge Muyldermans. A scholar is included among the top collaborators of Serge Muyldermans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Serge Muyldermans. Serge Muyldermans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hendrickx, Rik, Meng Yuan, Pieter Van Wielendaele, et al.. (2024). Allosteric inhibition of trypanosomatid pyruvate kinases by a camelid single-domain antibody. eLife. 13.
2.
Castro-López, J., Ana B. Sanz, Vladimı́r Farkaš, et al.. (2024). Broad Protection against Invasive Fungal Disease from a Nanobody Targeting the Active Site of Fungal β‐1,3‐Glucanosyltransferases. Angewandte Chemie International Edition. 63(34). e202405823–e202405823. 3 indexed citations
3.
Jovčevska, Ivana, et al.. (2022). Nanobodies targeting ABCC3 for immunotargeted applications in glioblastoma. Scientific Reports. 12(1). 22581–22581. 17 indexed citations
4.
Hu, Yaozhong, Feier Yang, Jing Lin, et al.. (2021). Selection of Specific Nanobodies against Lupine Allergen Lup an 1 for Immunoassay Development. Foods. 10(10). 2428–2428. 12 indexed citations
5.
Krasniqi, Ahmet, Matthias D’Huyvetter, Catarina Xavier, et al.. (2017). Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma. Molecular Cancer Therapeutics. 16(12). 2828–2839. 55 indexed citations
6.
Serneels, Lutgarde, Enrico Radaelli, Serge Muyldermans, et al.. (2017). Inactivation of γ‐secretases leads to accumulation of substrates and non‐Alzheimer neurodegeneration. EMBO Molecular Medicine. 9(8). 1088–1099. 36 indexed citations
7.
Odongo, Steven, Yann G.‐J. Sterckx, Benoı̂t Stijlemans, et al.. (2016). An Anti-proteome Nanobody Library Approach Yields a Specific Immunoassay for Trypanosoma congolense Diagnosis Targeting Glycosomal Aldolase. PLoS neglected tropical diseases. 10(2). e0004420–e0004420. 31 indexed citations
8.
Pardon, Els, Toon Laeremans, Sarah Triest, et al.. (2014). A general protocol for the generation of Nanobodies for structural biology. Nature Protocols. 9(3). 674–693. 554 indexed citations breakdown →
9.
D’Huyvetter, Matthias, Cécile Vincke, Catarina Xavier, et al.. (2014). Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody. Theranostics. 4(7). 708–720. 181 indexed citations
10.
Massa, Sam, Catarina Xavier, Jens De Vos, et al.. (2014). Site-Specific Labeling of Cysteine-Tagged Camelid Single-Domain Antibody-Fragments for Use in Molecular Imaging. Bioconjugate Chemistry. 25(5). 979–988. 149 indexed citations
11.
Zheng, Fang, Nick Devoogdt, Yannick Morias, et al.. (2014). Monitoring liver macrophages using nanobodies targeting Vsig4: Concanavalin A induced acute hepatitis as paradigm. Immunobiology. 220(2). 200–209. 27 indexed citations
12.
Xavier, Catarina, Ilse Vaneycken, Matthias D’Huyvetter, et al.. (2013). Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer. Journal of Nuclear Medicine. 54(5). 776–784. 190 indexed citations
13.
Butler, J.E., Nancy Wertz, Xiuzhu Sun, Joan K. Lunney, & Serge Muyldermans. (2012). Resolution of an immunodiagnostic dilemma: Heavy chain chimeric antibodies for species in which plasmocytomas are unknown. Molecular Immunology. 53(1-2). 140–148. 9 indexed citations
14.
Vincke, Cécile & Serge Muyldermans. (2012). Introduction to Heavy Chain Antibodies and Derived Nanobodies. Methods in molecular biology. 911. 15–26. 85 indexed citations
15.
Caljon, Guy, Benoı̂t Stijlemans, Dirk Saerens, et al.. (2012). Correction: Affinity Is an Important Determinant of the Anti-Trypanosome Activity of Nanobodies. PLoS neglected tropical diseases. 6(12). 3 indexed citations
16.
Broek, Bieke Van de, Nick Devoogdt, Antoine D’Hollander, et al.. (2011). Specific Cell Targeting with Nanobody Conjugated Branched Gold Nanoparticles for Photothermal Therapy. ACS Nano. 5(6). 4319–4328. 317 indexed citations
17.
Vaneycken, Ilse, Nick Devoogdt, Naomi Van Gassen, et al.. (2011). Preclinical screening of anti‐HER2 nanobodies for molecular imaging of breast cancer. The FASEB Journal. 25(7). 2433–2446. 265 indexed citations
18.
Muyldermans, Serge, et al.. (2010). Direct Injection of Functional Single-Domain Antibodies from E. coli into Human Cells. PLoS ONE. 5(12). e15227–e15227. 46 indexed citations
19.
Desmyter, Aline, Klaas Decanniere, Serge Muyldermans, & Lode Wyns. (2001). Antigen Specificity and High Affinity Binding Provided by One Single Loop of a Camel Single-domain Antibody. Journal of Biological Chemistry. 276(28). 26285–26290. 132 indexed citations
20.
Hamers‐Casterman, C., T. Atarhouch, Serge Muyldermans, et al.. (1993). Naturally occurring antibodies devoid of light chains. Nature. 363(6428). 446–448. 2424 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andreas Plückthun Breakdown of academic impact, for papers by Greg Winter Breakdown of academic impact, for papers by Pauline M. Rudd Breakdown of academic impact, for papers by K. Dane Wittrup Breakdown of academic impact, for papers by Renata Pasqualini Breakdown of academic impact, for papers by Georges Köhler Breakdown of academic impact, for papers by César Milstein Breakdown of academic impact, for papers by Manfred Wuhrer Breakdown of academic impact, for papers by Richard D. Cummings Breakdown of academic impact, for papers by Dimiter S. Dimitrov
Rankless by CCL
2026